Casado MÁ - Search Results

1

Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis.

Buti M, Domínguez-Hernández R, Palom A, Esteban R, Casado MÁ. Buti M, et al. Among authors: casado ma. Liver Int. 2023 Dec;43(12):2611-2614. doi: 10.1111/liv.15776. Epub 2023 Nov 2. Liver Int. 2023. PMID: 37916574

2

[Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha].

Buti M, Casado MA, Fosbrook L, Esteban R. Buti M, et al. Among authors: casado ma. Gastroenterol Hepatol. 1998 Apr;21(4):161-8. Gastroenterol Hepatol. 1998. PMID: 9633175 Spanish.

3

Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C.

Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Buti M, et al. Among authors: casado ma. J Hepatol. 2000 Oct;33(4):651-8. doi: 10.1034/j.1600-0641.2000.033004651.x. J Hepatol. 2000. PMID: 11059872

4

[Economic evaluation of combined therapy in chronic hepatitis C].

Casado MA, Buti M, Fosbrook L, Esteban R. Casado MA, et al. Gastroenterol Hepatol. 2000 Feb;23 Suppl 1:57-62. Gastroenterol Hepatol. 2000. PMID: 11968346 Review. Spanish. No abstract available.

5

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. Buti M, et al. Among authors: casado ma. Aliment Pharmacol Ther. 2003 Mar 1;17(5):687-94. doi: 10.1046/j.1365-2036.2003.01453.x. Aliment Pharmacol Ther. 2003. PMID: 12641518 Free article.

6

Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.

Buti M, Casado MA, Fosbrook L, Esteban R. Buti M, et al. Among authors: casado ma. Pharmacoeconomics. 2005;23(10):1043-55. doi: 10.2165/00019053-200523100-00007. Pharmacoeconomics. 2005. PMID: 16235977 Review.

7

Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients.

Buti M, Wong J, Casado MA, Esteban R. Buti M, et al. Among authors: casado ma. J Hepatol. 2006;44(1 Suppl):S60-4. doi: 10.1016/j.jhep.2005.11.014. Epub 2005 Nov 28. J Hepatol. 2006. PMID: 16360235

8

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.

Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R. Buti M, et al. Among authors: casado ma. Aliment Pharmacol Ther. 2006 Feb 1;23(3):409-19. doi: 10.1111/j.1365-2036.2006.02767.x. Aliment Pharmacol Ther. 2006. PMID: 16423000 Free article.

9

Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carte.

Buti M, Casado MA, Esteban R. Buti M, et al. Among authors: casado ma. Aliment Pharmacol Ther. 2007 Sep 1;26(5):705-16. doi: 10.1111/j.1365-2036.2007.03419.x. Aliment Pharmacol Ther. 2007. PMID: 17697204 Free article.

10

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Buti M, et al. Among authors: casado ma. J Hepatol. 2009 Oct;51(4):640-6. doi: 10.1016/j.jhep.2009.04.013. Epub 2009 May 20. J Hepatol. 2009. PMID: 19576651

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters